advanceCOR
Munich
About advanceCOR
advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $7.1M
- Last round: Series Unknown (May 2018)
- Website: advancecor.de
- Phone: +498985652010
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/advancecor-48677 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.